3-(氯甲基)-5-苯基-1,2,4-恶二唑 | 1201-68-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-(氯甲基)-5-苯基-1,2,4-恶二唑
• 中文别名: 3-(氯甲基)-5-苯基-1,2,4-氧二唑
• 英文名称: 3-chloromethyl-5-phenyl-1,2,4-oxadiazole
• 英文别名: 3-(chloromethyl)-5-phenyl-1,2,4-oxadiazole；3-chloromethyl-5-phenyl-[1,2,4]oxadiazole；3-(chloromethyl)-5-phenyl-1,2,4-oxadiazol；3-chloromethyl-5-phenyl[1,2,4]oxadiazole；3-Chlormethyl-5-phenyl-1,2,4-oxadiazol
• CAS: 1201-68-9
• 化学式: C₉H₇ClN₂O
• mdl: MFCD00084968
• 分子量: 194.62
• InChiKey: VEIXFEJMHJPUBS-UHFFFAOYSA-N

物化性质

• 熔点：
  64 °C
• 沸点：
  316.9±44.0 °C(Predicted)
• 密度：
  1.283±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  C
• 安全说明：
  S26,S36/37/39,S45
• 危险类别码：
  R34
• 海关编码：
  2934999090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P310,P332+P313,P362,P403+P233,P405,P501
• 危险品运输编号：
  3261
• 危险性描述：
  H315,H318,H335
• 储存条件：
  存储条件：2-8°C，密封，干燥，惰性气体环境。

SDS

Name:	3-(Chloromethyl)-5-phenyl-1 2 4-oxadiazole tech Material Safety Data Sheet
Synonym:
CAS:	1201-68-9

Section 1 - Chemical Product MSDS Name:3-(Chloromethyl)-5-phenyl-1 2 4-oxadiazole tech Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
1201-68-9	3-(Chloromethyl)-5-phenyl-1,2,4-oxadia		unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 1201-68-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 58 - 60 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H7ClN2O
Molecular Weight: 195

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 1201-68-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-(Chloromethyl)-5-phenyl-1,2,4-oxadiazole - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.*
Hazard Class: 8
UN Number: 3261
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 1201-68-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 1201-68-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 1201-68-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(氯甲基)-5-苯基-1,2,4-恶二唑 以55%的产率得到Triethyl 2-(5-phenyl-1,2,4-oxadiazol-3-yl)ethane-1,1,1-tricarboxylate
  参考文献：
  名称：

  Pseudodipeptides as MMP inhibitors

  摘要：

  本发明涉及化合物，特别是MMP抑制剂。本发明的化合物具有式(1)所示的结构。本发明特别适用于制药领域。本发明还涉及具有式(2)结构的标记化合物，以及将其用作检测细胞外基质金属蛋白酶的对比剂的用途。

  公开号：

  US08691753B2
• 作为产物：
  描述：

  N-(benzoyloxy)-2-chloroacetimidamide 以 甲苯 为溶剂， 生成 3-(氯甲基)-5-苯基-1,2,4-恶二唑
  参考文献：
  名称：

  作为高亲和力和选择性A2B腺苷受体拮抗剂的新型1,3-二丙基-8-（1-杂芳基甲基-1H-吡唑-4-基）-黄嘌呤衍生物。

  摘要：

  合成了一系列新的1,3-二丙基-8-（1-杂芳基甲基-1H-吡唑-4-基）-黄嘌呤衍生物作为A（2B）-AdoR拮抗剂，并评估了它们与A（2B）的结合亲和力），A（1），A（2A）和A（3）-AdoR。8-（1-（（（3-苯基-1,2,4-恶二唑-5-基）甲基）-1H-吡唑-4-基）-1,3-二丙基-1H-嘌呤-2,6（ 3H，7H）-二酮（4）对A（2B）-AdoR与A（1），A（2A）和A（3）-AdoRs的亲和力（K（i）= 1 nM）和选择性高（ A（1）/ A（2B），A（2A）/ A（2B）和A（3）/ A（2B）选择性比分别为370、1100和480）。本文介绍了这类新型化合物的合成和SAR。

  DOI：

  10.1016/j.bmcl.2005.10.002

文献信息

• Novel N-Substituted oseltamivir derivatives as potent influenza neuraminidase inhibitors: Design, synthesis, biological evaluation, ADME prediction and molecular docking studies
  作者：Jiqing Ye、Xiao Yang、Min Xu、Paul Kay-sheung Chan、Cong Ma

  DOI：10.1016/j.ejmech.2019.111635

  日期：2019.11

  strain. Moreover, the in silico ADME predictions showed that the selected compounds had comparable properties with oseltamivir carboxylate, which demonstrated the druggablity of these derivatives. Furthermore, molecular docking studies showed that the most potent compound 6f and 10i could adopt different modes of binding interaction with NA, which may provide novel solutions for treating oseltamivir-resistant

  新型有效的神经氨酸酶（NA）抑制剂的发现仍然是治疗由流感引起的传染病的有吸引力的方法。在这项研究中，我们描述了新型的N-取代的奥司他韦衍生物的设计和合成，以探测与NA的活性位有关的150腔。NA抑制研究表明，新衍生物显示出对临床流感病毒株NA的抑制活性，IC50值为nM。此外，计算机模拟ADME的预测结果表明，所选化合物与oseltamivir羧酸盐具有可比的特性，这证明了这些衍生物的药物相容性。此外，分子对接研究表明，最有效的化合物6f和10i可以采用与NA相互作用的不同模式，可能为治疗耐奥司他韦的流感提供新颖的解决方案。根据研究结果，我们认为化合物6f和10i作为新型抗病毒药物具有进一步研究的潜力。
• [EN] ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF<br/>[FR] DÉRIVÉS AMINOESTER D'ALKALOÏDES ET COMPOSITION MÉDICINALE LES COMPRENANT
  申请人：CHIESI FARMA SPA

  公开号：WO2011160919A1

  公开（公告）日：2011-12-29

  The present invention relates to alkaloid aminoester derivatives acting as muscarinic receptor antagonists, processes for their preparation, compositions comprising them and therapeutic uses thereof.

  本发明涉及作为毒蕈碱受体拮抗剂的生物碱氨基酸酯衍生物，它们的制备方法，包含它们的组合物及其治疗用途。
• [EN] QUINUCLIDINE ESTERS OF 1-AZAHETEROCYCLYLACETIC ACID AS ANTIMUSCARINIC AGENTS, PROCESS FOR THEIR PREPARATION AND MEDICINAL COMPOSITIONS THEREOF<br/>[FR] ESTERS DE QUINUCLIDINE ET D'ACIDE 1-AZAHÉTÉROCYCLYLACÉTIQUE UTILISÉS COMME AGENTS ANTIMUSCARINIQUES, PROCÉDÉ POUR LEUR PRÉPARATION ET COMPOSITIONS MÉDICINALES CORRESPONDANTES
  申请人：CHIESI FARMA SPA

  公开号：WO2013098145A1

  公开（公告）日：2013-07-04

  The invention relates to compounds of formula (I), wherein A, R1, R2, X, m and n are as defined in the specification, as selective M3 receptor antagonists, process for their preparation, composition comprising them and the therapeutic use thereof. Said compounds may be used in the treatment of, inter alia, a respiratory disease such as asthma and COPD.

  本发明涉及通式(I)的化合物，其中A、R1、R2、X、m和n如说明书中所定义，作为选择性M3受体拮抗剂，其制备方法，包含它们的组合物及其治疗用途。这些化合物可用于治疗，特别是呼吸系统疾病，如哮喘和慢性阻塞性肺病(COPD)。
• [EN] TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF<br/>[FR] INHIBITEURS DE LA KINASE TRKA, COMPOSITIONS EN CONTENANT ET MÉTHODES ASSOCIÉES
  申请人：MERCK SHARP & DOHME

  公开号：WO2013009582A1

  公开（公告）日：2013-01-17

  The present invention is directed to compounds of formula I and la: which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

  本发明涉及式I和la化合物，它们是原肌球蛋白相关激酶（Trk）家族蛋白激酶抑制剂，因此可用于治疗疼痛、炎症、癌症、再狭窄、动脉粥样硬化、银屑病、血栓形成、与脱髓鞘或髓鞘形成障碍相关的疾病、紊乱、损伤或功能障碍，或与神经生长因子（NGF）受体TrkA异常活性相关的疾病或紊乱。
• ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF
  申请人：AMARI Gabriele

  公开号：US20110311459A1

  公开（公告）日：2011-12-22

  The present invention relates to alkaloid aminoester compounds which act as muscarinic receptor antagonists, processes for the preparation of such a compound, compositions which contain such a compound, and therapeutic uses of such a compound.

  本发明涉及作为毒蕈碱受体拮抗剂的生物碱氨基酯化合物，制备此类化合物的方法，含有此类化合物的组合物，以及此类化合物的治疗用途。